ACHV

Achieve Life Sciences, Inc. (ACHV) | Rumor.io

Achieve Life Sciences

ACHV

Attention (50-day avg)0%

Attention rank (50-day avg)#1,985

Bullish sentiment (50-day avg)94%

Price to earnings ratio-6.2

Market capitalization797.5M

Earnings per share-1.66

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-54.6M

Social

What share of all stock conversation is about ACHV?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Aug 14

Morgan Stanley initiated coverage of $ACHV with an Overweight rating and a $13 target, citing potential in cytisinicline, a smoking-cessation treatment Achieve plans to resubmit to the FDA in Q4.
Achieve Life Sciences anticipates potential FDA approval for cytisinicline in the first half of 2027, which will be followed by a U.S. commercial launch of the treatment for nicotine dependence.
The company has entered into an ATM sale agreement with Jefferies for up to $150 million in common stock, with a $150 million capacity, up to 20.7M shares at market via Jefferies.

Generated by AI

Sentiment

Of the messages about ACHV that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	96.67% +3.22	92.46% +3.92
Bearish	—	—	3.33% -3.22	7.54% -3.92

Bullish· May 12

$ACHV has the potential to reach $25 per share based on peak sales, making it undervalued on current prices.
The company's new management team, led by a driven CEO, has the expertise to get FDA approval and is a major positive factor for the stock.
With a healthy balance sheet, a national crisis creating market opportunities, and a US-based supply chain, the upside for $ACHV is still bright despite some concerns about share issuance.

Bearish· Apr 16

The company's dilution of shares will likely lead to a price of $12-13, and the stock's market capitalization will need to increase by 819% to double the price.
The financing for the company's clinical trial was likely contingent on the CEO being replaced, indicating poor execution and a possible negative impact on the company's future prospects.
The company's share price may be artificially inflated and could decline once the additional 49 million warrants are exercised, potentially leading to a short-term price drop.

Generated by AI

Topics

Of the messages about ACHV that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	50%	97.62%	85.71%	62.98%
Technical Analysis	50%	2.38%	14.29%	20.51%
Earnings	0%	0%	0%	0.36%
Analysts	0%	0%	0%	8.53%
Controversies	0%	0%	0%	0.36%
Macro	0%	0%	0%	7.26%

Earnings· Feb 21

Achieve Life Sciences, Inc. ($ACHV) is expected to report earnings on Thursday, February 22.
The upcoming earnings report may have a significant impact on the company's stock price.
Investors are likely to be closely watching the report for any updates on the company's performance.

Announcements· Apr 16

Achieve Life Sciences, Inc. (ACHV) announced a private placement of up to $354 million, with $180 million in upfront financing and an additional $174 million from warrants exercisable post-approval.
The company also announced the appointment of a new CEO, Andrew Goldberg, and the addition of two new board members, strengthening its leadership and positioning for the development and launch of cytisinicline.
The private placement and new leadership are seen as key catalysts for the company, with some analysts noting that the dilution risk has been cleared and the company is now on track for a potential launch of its smoking/vaping quit drug, cytisinicline.

Technical Analysis· Jul 31

ACHV has shown strength in holding up against a red market and potential panic sellers, with some traders sticking with the stock despite short sellers' efforts to drive the price down.
Technical analysis suggests a potential parabolic run to $18.30+ if ACHV breaks above $14.20, with some traders noting a consolidation range of $12.90-$14.20 and a possible inverse head and shoulders pattern.
ACHV has a major liquidity zone at $13.50, with bulls potentially using the $12.00 level as support and entering the trade there, while resistances are noted around $18.30 and $20.60+.

Generated by AI

Community

Of the messages about ACHV, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	18.6%	35%	61.63%
Newcomers	0%	81.4%	65%	38.37%

Regulars· Apr 16

The private placement of up to $354 million, including $180 million upfront, has been announced, which is expected to provide Achieve Life Sciences with sufficient funds for its operations and future developments.
The company has de-risked its manufacturing process by transferring cytisinicline production to Ohio-based Adare Pharma Solutions, and it is now ready to resubmit the NDA with the new supplier.
Achieve Life Sciences is expected to receive a CRL (complete response letter) for cytisinicline, which may delay its PDUFA (prescription drug user fee act) date, but the company is hopeful of imminent approval and launch in 1H27.

Newcomers· Jul 21

Many newcomers are holding ACHV (Achieve Life Sciences) and expressing frustration with the current price slump, with prices at $6.24 and a change of -0.47846889952152094.
The recent losses are causing pain for many investors, with several users feeling "lonely" and "miserable" with the underwater portfolio.
Users are sharing their losses and asking others to do the same, creating a sense of community among those nursing losses in Achieve Life Sciences.

Generated by AI

News

Achieve Life Sciences: Thesis Intact, Setup Remains Constructive (Rating Downgrade) (ACHV)

Achieve Life Sciences is rated a 'buy' as it nears a second NDA resubmission after resolving prior manufacturing issues. Click for this ACHV stock update.

6d agoSeeking Alpha

Achieve Life Sciences: A Funded Manufacturing Reset, Not A Broken Clinical Thesis

8d agoSeeking Alpha

Achieve Life Sciences Announced Granting of New Hire Inducement Awards

SEATTLE and VANCOUVER, British Columbia, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that Achieve’s board of directors approved stock option grants to purchase an aggregate of 315,000 shares of its common stock and restricted stock unit (“RSU”) awards covering an aggregate of 283,000 share

26d agoYahoo Finance

ACHV: Looking Ahead to Resubmission

By John Vandermosten, CFA NASDAQ: ACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ: ACHV) reported second quarter results, introducing a number of new faces and regulatory updates since the previous financial update in May. Achieve has added new individuals to both the executive ranks and the board. The company has enhanced its commercial leadership, Chemistry,

1mo agoYahoo Finance

Analysts Offer Insights on Healthcare Companies: Achieve Life Sciences (ACHV) and Idexx Laboratories (IDXX)

Detailed price information for Achieve Life Sciences Inc (ACHV-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Exclusive BAC Article: Achieve Life Sciences; NDA Resubmission Cytisinicline Smoking Cessation Q4 2026, 1st Half 2027 Commercial Launch, Expansion Vaping Cessation, And Catalysts (NASDAQ:ACHV)

1mo agoSeeking Alpha

Also Discussed

Investors talking about ACHV also mention

#	Name	Attention
1	Avalon Holdings Corp. Class A Common StockAWX	0%new
2	Xenetic Biosciences, Inc.XBIO	0%new
3	Bio-Path Holdings Inc.BPTH	0%0
4	Capricor Therapeutics, Inc.CAPR	0.34%+0.25
5	YTEN - Yield10 Bioscience, Inc.	——
6	vTv Therapeutics Inc. Class A Common StockVTVT	0%new
7	Globus Maritime Limited Common StockGLBS	0%new
8	STAF - Staffing 360 Solutions, Inc.	——
9	Arcadia Biosciences Inc.RKDA	0.01%0
10	OPGN - OpGen, Inc.	——

Achieve Life Sciences, Inc.

Healthcare
Biotechnology

Achieve Life Sciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing cytisinicline, a treatment designed to address nicotine dependence and support smoking cessation. Its core work centers on advancing this non-opioid, plant-derived therapy for adults seeking help with nicotine withdrawal and tobacco use disorder. The company operates in the healthcare and biotechnology sectors, where it contributes to efforts aimed at expanding pharmacological options for addiction treatment. Achieve Life Sciences’ current business is centered on cytisinicline across key markets in North America and the United Kingdom, reflecting its focus on regulated prescription therapies for nicotine addiction. Headquartered in Bothell, Washington, with operations also connected to Vancouver, British Columbia, the company remains dedicated to a single therapeutic area and a narrowly defined pharmaceutical portfolio.

Website

Location

22722 29th Dr. SE

Bothell, WA, 98021

United States

Social

What share of all stock conversation is about ACHV?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Aug 14

Morgan Stanley initiated coverage of $ACHV with an Overweight rating and a $13 target, citing potential in cytisinicline, a smoking-cessation treatment Achieve plans to resubmit to the FDA in Q4.
Achieve Life Sciences anticipates potential FDA approval for cytisinicline in the first half of 2027, which will be followed by a U.S. commercial launch of the treatment for nicotine dependence.
The company has entered into an ATM sale agreement with Jefferies for up to $150 million in common stock, with a $150 million capacity, up to 20.7M shares at market via Jefferies.

Generated by AI

Sentiment

Of the messages about ACHV that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	96.67% +3.22	92.46% +3.92
Bearish	—	—	3.33% -3.22	7.54% -3.92

Bullish· May 12

$ACHV has the potential to reach $25 per share based on peak sales, making it undervalued on current prices.
The company's new management team, led by a driven CEO, has the expertise to get FDA approval and is a major positive factor for the stock.
With a healthy balance sheet, a national crisis creating market opportunities, and a US-based supply chain, the upside for $ACHV is still bright despite some concerns about share issuance.

Bearish· Apr 16

The company's dilution of shares will likely lead to a price of $12-13, and the stock's market capitalization will need to increase by 819% to double the price.
The financing for the company's clinical trial was likely contingent on the CEO being replaced, indicating poor execution and a possible negative impact on the company's future prospects.
The company's share price may be artificially inflated and could decline once the additional 49 million warrants are exercised, potentially leading to a short-term price drop.

Generated by AI

Topics

Of the messages about ACHV that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	50%	97.62%	85.71%	62.98%
Technical Analysis	50%	2.38%	14.29%	20.51%
Earnings	0%	0%	0%	0.36%
Analysts	0%	0%	0%	8.53%
Controversies	0%	0%	0%	0.36%
Macro	0%	0%	0%	7.26%

Earnings· Feb 21

Achieve Life Sciences, Inc. ($ACHV) is expected to report earnings on Thursday, February 22.
The upcoming earnings report may have a significant impact on the company's stock price.
Investors are likely to be closely watching the report for any updates on the company's performance.

Announcements· Apr 16

Achieve Life Sciences, Inc. (ACHV) announced a private placement of up to $354 million, with $180 million in upfront financing and an additional $174 million from warrants exercisable post-approval.
The company also announced the appointment of a new CEO, Andrew Goldberg, and the addition of two new board members, strengthening its leadership and positioning for the development and launch of cytisinicline.
The private placement and new leadership are seen as key catalysts for the company, with some analysts noting that the dilution risk has been cleared and the company is now on track for a potential launch of its smoking/vaping quit drug, cytisinicline.

Technical Analysis· Jul 31

ACHV has shown strength in holding up against a red market and potential panic sellers, with some traders sticking with the stock despite short sellers' efforts to drive the price down.
Technical analysis suggests a potential parabolic run to $18.30+ if ACHV breaks above $14.20, with some traders noting a consolidation range of $12.90-$14.20 and a possible inverse head and shoulders pattern.
ACHV has a major liquidity zone at $13.50, with bulls potentially using the $12.00 level as support and entering the trade there, while resistances are noted around $18.30 and $20.60+.

Generated by AI

Community

Of the messages about ACHV, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	18.6%	35%	61.63%
Newcomers	0%	81.4%	65%	38.37%

Regulars· Apr 16

The private placement of up to $354 million, including $180 million upfront, has been announced, which is expected to provide Achieve Life Sciences with sufficient funds for its operations and future developments.
The company has de-risked its manufacturing process by transferring cytisinicline production to Ohio-based Adare Pharma Solutions, and it is now ready to resubmit the NDA with the new supplier.
Achieve Life Sciences is expected to receive a CRL (complete response letter) for cytisinicline, which may delay its PDUFA (prescription drug user fee act) date, but the company is hopeful of imminent approval and launch in 1H27.

Newcomers· Jul 21

Many newcomers are holding ACHV (Achieve Life Sciences) and expressing frustration with the current price slump, with prices at $6.24 and a change of -0.47846889952152094.
The recent losses are causing pain for many investors, with several users feeling "lonely" and "miserable" with the underwater portfolio.
Users are sharing their losses and asking others to do the same, creating a sense of community among those nursing losses in Achieve Life Sciences.

Generated by AI

Achieve Life Sciences

Social

Aug 14

Bullish· May 12

Bearish· Apr 16

Earnings· Feb 21

Announcements· Apr 16

Technical Analysis· Jul 31

Regulars· Apr 16

Newcomers· Jul 21

Achieve Life Sciences: Thesis Intact, Setup Remains Constructive (Rating Downgrade) (ACHV)

Achieve Life Sciences: A Funded Manufacturing Reset, Not A Broken Clinical Thesis

Achieve Life Sciences Announced Granting of New Hire Inducement Awards

ACHV: Looking Ahead to Resubmission

Analysts Offer Insights on Healthcare Companies: Achieve Life Sciences (ACHV) and Idexx Laboratories (IDXX)

Exclusive BAC Article: Achieve Life Sciences; NDA Resubmission Cytisinicline Smoking Cessation Q4 2026, 1st Half 2027 Commercial Launch, Expansion Vaping Cessation, And Catalysts (NASDAQ:ACHV)

Also Discussed

Achieve Life Sciences, Inc.

Company Information

Location

Achieve Life Sciences: Thesis Intact, Setup Remains Constructive (Rating Downgrade) (ACHV)

Achieve Life Sciences: A Funded Manufacturing Reset, Not A Broken Clinical Thesis

Achieve Life Sciences Announced Granting of New Hire Inducement Awards

ACHV: Looking Ahead to Resubmission

Analysts Offer Insights on Healthcare Companies: Achieve Life Sciences (ACHV) and Idexx Laboratories (IDXX)

Exclusive BAC Article: Achieve Life Sciences; NDA Resubmission Cytisinicline Smoking Cessation Q4 2026, 1st Half 2027 Commercial Launch, Expansion Vaping Cessation, And Catalysts (NASDAQ:ACHV)

Also Discussed

Social

Aug 14

Bullish· May 12

Bearish· Apr 16

Earnings· Feb 21

Announcements· Apr 16

Technical Analysis· Jul 31

Regulars· Apr 16

Newcomers· Jul 21